Denosumab versus zoledronic acid in metastatic breast cancer: A retrospective observational analysis of 24-dose regimens on analgesia and skeletal-related event prevention
Dmab showed consistent superior effect than ZA in reducing bone pain in metastatic BC, yet both treatments delivered similar protection against SREs and the need for radiotherapy or surgery.
Authors
- Paola Bracchi
- Francesca Ricchini (ORCID: https://orcid.org/0000-0002-5868-3954)
- Augusto Caraceni (ORCID: https://orcid.org/0000-0002-0375-6204)
- Giulia Bianchi (ORCID: https://orcid.org/0000-0003-3630-4527)
- Luca Zambelli
- Rosalba Miceli (ORCID: https://orcid.org/0000-0003-0954-375X)
- Ernesto Zecca (ORCID: https://orcid.org/0000-0003-1689-0370)
- Giacomo Massa (ORCID: https://orcid.org/0000-0003-4637-9821)
- Gabriele Tinè (ORCID: https://orcid.org/0000-0003-1762-1375)
- Noemi Simeone
- Silvia Lo Dico
- Alessandra Pigni (ORCID: https://orcid.org/0000-0003-1869-965X)
Institutions
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- The Breast
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1016/j.breast.2025.104565
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05